The mechanism and overcome of resistance to anti-VEGF antibody, bevacizumab in colon cancer

Research Project

Project/Area Number	22591478
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Single-year Grants
Section	一般
Research Field	Digestive surgery
Research Institution	International University of Health and Welfare
Principal Investigator	TAKAHASHI Yutaka 国際医療福祉大学, 臨床医学研究センター, 教授 (10179541)
Co-Investigator(Kenkyū-buntansha)	KITADAI Yashuhiko 広島大学, 大学院・医歯薬総合研究科, 准教授 (10304437)
Project Period (FY)	2010 – 2012
Project Status	Completed (Fiscal Year 2012)
Budget Amount *help	¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000) Fiscal Year 2012: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000) Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000) Fiscal Year 2010: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Keywords	大腸癌外科学 / Bevacizumab / VEGF / 耐性 / colon cancer / 抗血管新生療法 / 大腸癌
Research Abstract	We studied the mechanism and overcome of resistance to anti-VEGF antibody , bevacizumab. We could not find any upregulated genes in transplanted tumors and clinical tumors which were resistant to bevacizumab while bevacizumab therapies by several microarray studies. These results suggest that the resistance to anti-VEGF would be rare rather than conventional cancer drugs and other molecular targeting drugs.

Report

(4 results)